To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Prospective study of grow… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Prospective study of growth and bone mass in Swedish children treated with the modified Atkins diet.

Journal article
Authors Anna Svedlund
Tove Hallböök
P Magnusson
Jovanna Dahlgren
Diana Swolin-Eide
Published in European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
Volume 23
Issue 4
Pages 629-638
ISSN 1532-2130
Publication year 2019
Published at Institute of Clinical Sciences, Department of Pediatrics
Pages 629-638
Language en
Links dx.doi.org/10.1016/j.ejpn.2019.04.0...
www.ncbi.nlm.nih.gov/entrez/query.f...
Keywords Adolescent, Bone Density, Child, Child, Preschool, Diet, High-Protein Low-Carbohydrate, methods, Drug Resistant Epilepsy, diet therapy, Female, Humans, Infant, Longitudinal Studies, Male, Prospective Studies, Sweden, Treatment Outcome
Subject categories Pediatrics

Abstract

The modified Atkins diet (MAD) is a less restrictive treatment option than the ketogenic diet (KD) for intractable epilepsy and some metabolic conditions. Prolonged KD treatment may decrease bone mineralization and affect linear growth; however, long-term studies of MAD treatment are lacking. This study was designed to assess growth, body composition, and bone mass in children on MAD treatment for 24 months.Thirty-eight patients, mean age (SD) 6.1 years (4.8 years), 21 girls, with intractable epilepsy (n = 22), glucose transporter type 1 deficiency syndrome (n = 7), or pyruvate dehydrogenase complex deficiency (n = 9) were included. Body weight, height, body mass index (BMI), bone mass, and laboratory tests (calcium, phosphorus, magnesium, alkaline phosphatase, cholesterol, 25-hydroxyvitamin D, insulin-like growth factor-I and insulin-like growth factor binding protein 3) were assessed at baseline and after 24 months of MAD treatment.Approximately 50% of the patients responded with more than 50% seizure reduction. Weight and height standard deviation score (SDS) were stable over 24 months, whereas median (minimum - maximum) BMI SDS increased from 0.2 (-3.3 to 4.5) to 0.7 (-0.9 to 2.6), p < 0.005. No effects were observed for bone mass (total body, lumbar spine and hip) or fat mass.The MAD was efficient in reducing seizures, and no negative effect was observed on longitudinal growth or bone mass after MAD treatment for 24 months.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?